Fundraising Fox
Immunovant
New York, US · Founded 2018 · 282 employees on LinkedIn · 2 known investors
Find your way into Immunovant
287 people in our graph share verified history with the Immunovant team — schools, employers, funds. One of them is your warm intro.
Takashi Furukawaunlockedknows Jay Stout · together at San Bio (overlapped)
knows the team · via Immunovant
knows the team · via Achillion Pharmaceuticals, Inc.
knows the team · via Albany Medical College
×8knows the team · via University of Nebraska-Lincoln
Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
Founders & leadership
CV
Christopher Van TuylExecutive
MG
Michael GeffnerChief Medical Officer2024–2025Michael Geffner is an Executive Officer at Immunovant, a clinical-stage immunology company developing anti-FcRn targeted therapies for autoimmune diseases. He is a physician with board certifications in neurology with special qualification in child neurology and pediatrics, and has held clinical research and medical affairs leadership roles.
JS
Jay StoutChief Technology OfficerJay Stout is Executive Officer at Immunovant, a clinical-stage immunology company developing anti-FcRn therapies for autoimmune diseases. He has expertise in bioprocessing, including cell culture, fermentation, downstream processing, and formulation, and has supported product licensure and manufacturing optimization across biologics development.
ER
Eva Renee BarnettExecutive
BM
Bill MaciasExecutive
Board
Investors · 2
Also in the syndicate · 1
Roivant Sciences
Funding
SEC filings, press & company announcements$1B disclosed across 2 of 3 rounds · 2025–2026
- $550MraisedDec 2025 · 2 sources
Roivant Sciences
Source ↗
▶$450MraisedJan 2025 · 11 investors · PharmaceuticalsRule 506(b)
▶$450MraisedJan 2025 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christopher Van TuylExecutive Officer
- Michael GeffnerExecutive Officer
- Andrew FromkinDirector
- Atul PandeDirector
- George MigauskyDirector
- Eric VenkerDirector
- Frank TortiDirector
- Pete SalzmannExecutive Officer, Director
- Jay StoutExecutive Officer
- Melanie GloriaExecutive Officer
- Eva Renee BarnettExecutive Officer
- Bill MaciasExecutive Officer
- Douglas HughesDirector
- Offering amount
- $450M
- Amount sold
- $450M
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Signant Health34 shared keywordsSignant Health provides software platforms and clinical trial solutions for life sciences companies to manage patient-reported outcomes, evidence generation, and digital endpoints in drug development programs across multiple therapeutic areas.
Guardant Health32 shared keywordsGuardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease. The company serves oncologists, patients, and biopharmaceutical firms with FDA-approved tests for cancer screening, early-stage risk assessment, and treatment selection.
Companies competing with Immunovant for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Immunovant do?
- Immunovant is a clinical-stage immunology company developing targeted therapies based on anti-FcRn technology for people with autoimmune diseases.
- Who are Immunovant's investors?
- Immunovant's investors include Altium Capital.
- How much funding has Immunovant raised?
- Immunovant has disclosed $1B raised across 2 of its 3 known rounds.
- Where is Immunovant headquartered?
- Immunovant is headquartered in New York, US.